Dean Kilby

Founder & Director of Simplr Health Group, Biomedical Scientist

Dean Kilby is a pioneering leader in health innovation, with a career spanning scientific research, clinical application, and transformative health solutions. As the founder of Simplr Health Group, Dean is dedicated to addressing the rising impact of metabolic dysfunction, including type 2 diabetes, autoimmune diseases, and cancer. His work has been instrumental in advancing the prevention, reversal, and management of these conditions through cutting-edge science and personalized health strategies.

Dean’s contributions to regenerative medicine are internationally recognized. He is pioneering clinical applications of cell therapies across Australia, the U.S., Indonesia, and India. Dean also made a significant impact during the COVID-19 pandemic, being the first to add a neutralizing antibody test for SARS-CoV-2 to the Australian Register of Therapeutic Goods (ARTG). Furthermore, he discovered a novel method to detect and measure nasal mucosal neutralizing antibodies at the point of care, which was published in Scientific Reports, a journal by Nature Publishing Group.

Dean graduated with first-class honours in biotechnology (molecular virology) and completed post-graduate training in molecular medicine, focusing on protein biochemistry and molecular cell biology. His career has bridged the pharmaceutical industry, medical communications, and scientific consulting, with expertise ranging from reversing metabolic syndrome to advancing regenerative medicine.

Beyond his scientific accomplishments, Dean has over 15 years of experience as a transformational performance coach and a leading trainer across the ANZ region. His unique combination of scientific expertise, clinical innovation, and coaching excellence has established him as a visionary in creating impactful health solutions globally.